B. Riley set a $10.00 price target on Amyris (NASDAQ:AMRS) in a report released on Tuesday, March 20th, Marketbeat Ratings reports. The brokerage currently has a buy rating on the biotechnology company’s stock. B. Riley also issued estimates for Amyris’ Q1 2018 earnings at ($0.38) EPS, Q2 2018 earnings at ($0.21) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at $0.17 EPS, FY2018 earnings at ($0.52) EPS, Q1 2019 earnings at ($0.12) EPS, Q2 2019 earnings at $0.00 EPS, Q3 2019 earnings at $0.07 EPS, Q4 2019 earnings at $0.21 EPS and FY2019 earnings at $0.16 EPS.
Several other research analysts have also recently weighed in on AMRS. Cowen reiterated a hold rating and set a $4.00 price target on shares of Amyris in a research report on Wednesday, November 29th. HC Wainwright set a $15.00 price objective on Amyris and gave the company a buy rating in a report on Wednesday, November 29th. ValuEngine lowered Amyris from a sell rating to a strong sell rating in a research note on Friday, December 1st. Finally, Zacks Investment Research lowered Amyris from a hold rating to a sell rating in a research note on Tuesday, January 30th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $8.19.
Amyris stock traded down $0.13 during midday trading on Tuesday, reaching $6.80. The company’s stock had a trading volume of 591,275 shares, compared to its average volume of 566,074. Amyris has a 52-week low of $1.86 and a 52-week high of $10.65. The stock has a market cap of $296.93, a PE ratio of -2.23 and a beta of 0.13. The company has a debt-to-equity ratio of -0.78, a quick ratio of 0.82 and a current ratio of 0.92.
Amyris (NASDAQ:AMRS) last announced its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.07 by ($0.24). The firm had revenue of $80.59 million during the quarter, compared to analysts’ expectations of $68.14 million. The firm’s revenue was up 262.4% on a year-over-year basis. During the same period last year, the firm posted ($0.09) EPS. sell-side analysts predict that Amyris will post -0.59 EPS for the current fiscal year.
In other Amyris news, insider John Melo sold 10,776 shares of Amyris stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $4.68, for a total value of $50,431.68. Following the sale, the insider now owns 83,172 shares in the company, valued at $389,244.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 11.30% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the stock. Creative Planning purchased a new stake in shares of Amyris in the 4th quarter valued at $188,000. KBC Group NV grew its stake in Amyris by 228.4% during the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 41,834 shares in the last quarter. Compagnie Lombard Odier SCmA grew its stake in Amyris by 60.0% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 39,000 shares in the last quarter. Hudson Bay Capital Management LP acquired a new position in Amyris during the 4th quarter worth $451,000. Finally, Tanaka Capital Management Inc. grew its stake in Amyris by 72.0% during the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock worth $1,691,000 after purchasing an additional 221,295 shares in the last quarter. Hedge funds and other institutional investors own 22.27% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was first published by Macon Daily and is the property of of Macon Daily. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://macondaily.com/2018/04/12/amyris-amrs-given-a-10-00-price-target-at-b-riley-updated-updated-updated.html.
Amyris, Inc provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.